0001104659-23-080692.txt : 20230713
0001104659-23-080692.hdr.sgml : 20230713
20230713140200
ACCESSION NUMBER: 0001104659-23-080692
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230711
FILED AS OF DATE: 20230713
DATE AS OF CHANGE: 20230713
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blumenkranz Mark S.
CENTRAL INDEX KEY: 0001614869
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36080
FILM NUMBER: 231086444
MAIL ADDRESS:
STREET 1: C/O 1LIFE HEALTHCARE, INC.
STREET 2: ONE EMBARCADERO CENTER, SUITE 1900
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IVERIC bio, Inc.
CENTRAL INDEX KEY: 0001410939
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208185347
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: (609) 474-6755
MAIL ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Ophthotech Corp.
DATE OF NAME CHANGE: 20070828
4
1
tm2321002-12_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-07-11
1
0001410939
IVERIC bio, Inc.
ISEE
0001614869
Blumenkranz Mark S.
C/O IVERIC BIO, INC.
8 SYLVAN WAY
PARSIPPANY
NJ
07054
1
0
0
0
0
Common Stock
2023-07-11
4
D
0
32088
D
0
D
Restricted Stock Units
2023-07-11
4
D
0
5000
D
Common Stock
5000
0
D
Restricted Stock Units
2023-07-11
4
D
0
7500
D
Common Stock
7500
0
D
Stock Option (Right to Buy)
4.48
2023-07-11
4
D
0
31000
D
2030-07-14
Common Stock
31000
0
D
Stock Option (Right to Buy)
6.82
2023-07-11
4
D
0
15500
D
2031-05-18
Common Stock
15500
0
D
Stock Option (Right to Buy)
9.94
2023-07-11
4
D
0
23186
D
2032-05-11
Common Stock
23186
0
D
On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
/s/ Todd D.C. Anderman, as Attorney-in-Fact for Mark S. Blumenkranz
2023-07-13